ReviewChildren (Basel, Switzerland)2018
Current and Emerging Therapies in the Management of Hypoxic Ischemic Encephalopathy in Neonates.
Review in Children (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Post-Asphyxial Aftercare and Management of Neonates in Low- and Middle-Income Countries: A Systematic Evidence Synthesis.Neonatology · 2025Pooled it
- Comparison of Different Adjuvant Therapies for Hypothermia in Neonates with Hypoxic-Ischemic Encephalopathy: A Systematic Review and Network Meta-Analysis.Indian journal of pediatrics · 2024Pooled it
- Biomarkers of hypoxic-ischemic encephalopathy: a systematic review.World journal of pediatrics : WJP · 2023Pooled it
- Stem Cell Therapy for Neonatal Hypoxic-Ischemic Encephalopathy: A Systematic Review of Preclinical Studies.International journal of molecular sciences · 2021Pooled it
- Pooled it
- Comparative Efficacy and Safety of Neuroprotective Therapies for Neonates With Hypoxic Ischemic Encephalopathy: A Network Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Magnesium Sulfate in Neonatal Hypoxic-Ischemic Encephalopathy: Bridging the Gap Between Molecular Neuroprotection and Clinical Outcomes.Current issues in molecular biology · 2026Review
- Neurofunctional and Clinical Effects of Intranasal Human Recombinant Nerve Growth Factor in Children with Acquired Brain Injury.Pharmaceuticals (Basel, Switzerland) · 2026Review
- N-Acetylcysteine Reduces Tissue Injury Induced by Oxygen-Glucose Deprivation in an Organotypic Culture of Mouse Cerebral Cortex Slices.Children (Basel, Switzerland) · 2026Article
- Multi-modal screening for synergistic neuroprotection of mild extremely preterm brain injury.Bioengineering & translational medicine · 2026Article
- Comparison of the prognosis of asphyxiated infants receiving hypothermia therapy with those receiving erythropoietin: a prospective cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- AI-Driven Quantitative Metabolomics for Early and Precise HIE Diagnosis: Challenges and Solutions.ACS omega · 2025Review
- Nerve Growth Factor in Pediatric Brain Injury: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Automated Neuroprognostication Via Machine Learning in Neonates with Hypoxic-Ischemic Encephalopathy.Annals of neurology · 2025Article
- Altered sleep and inflammation are related to outcomes in neonatal encephalopathy.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Can miRNAs in MSCs-EVs Offer a Potential Treatment for Hypoxic-ischemic Encephalopathy?Stem cell reviews and reports · 2025Review
- Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments.World journal of pediatrics : WJP · 2024Review
- Article
- Neuroprotective Effect of Melatonin in a Neonatal Hypoxia-Ischemia Rat Model Is Regulated by the AMPK/mTOR Pathway.Journal of the American Heart Association · 2024Article
- Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Neonatal hypoxic ischemic encephalopathy (HIE) presents a significant clinical burden with its high mortality and morbidity rates globally. Therapeutic hypothermia (TH) is now standard of care for infants with moderate to severe HIE, but has not definitively changed outcomes in severe HIE. In this review, we discuss newer promising markers that may help the clinician identify severity of HIE. Therapies that are beneficial and agents that hold promise for neuroprotection are described, both for use either alone or as adjuncts to TH. These include endogenous pathway modifiers such as erythropoietin and analogues, melatonin, and remote ischemic post conditioning. Stem cells have therapeutic potential in this condition, as in many other neonatal conditions. Of the agents listed, only erythropoietin and analogues are currently being evaluated in large randomized controlled trials (RCTs). Exogenous therapies such as argon and xenon, allopurinol, monosialogangliosides, and magnesium sulfate continue to be investigated. The recognition of tertiary mechanisms of brain damage has opened up new research into therapies not only to attenuate brain damage but also to promote cell repair and regeneration in a developmentally disorganized brain long after the perinatal insult. These alternative modalities may be especially important in mild HIE and in areas of the world where there is limited access to expensive hypothermia equipment and services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.